JAHA:高血钾症伴Brugada 表型患者的临床特征研究

2019-01-25 MedSci MedSci原创

严重的代谢紊乱也可引起Brugada 综合征样的心电图,成为Brugada 样表型(BrPh),本研究的目的旨在评估BrPh患者的临床特征和预后,并阐明BrPh致高血钾症的原理。本研究纳入分析了15例高血钾症伴BrPh患者的临床特征和预后,并将其与高血钾症不伴BrPh患者进行比较。在6年随访的这段时间里,15名高血钾症伴BrPh患者均可以因血钾水平正常后症状消失。6名患者(40%)表现为恶性心律失

严重的代谢紊乱也可引起Brugada 综合征样的心电图,成为Brugada 样表型(BrPh),本研究的目的旨在评估BrPh患者的临床特征和预后,并阐明BrPh致高血钾症的原理。

本研究纳入分析了15例高血钾症伴BrPh患者的临床特征和预后,并将其与高血钾症不伴BrPh患者进行比较。在6年随访的这段时间里,15名高血钾症伴BrPh患者均可以因血钾水平正常后症状消失。6名患者(40%)表现为恶性心律失常,6名患者在住院期间死亡。多元回归分析发现,对于高血钾症患者而言,高血钾水平(OR:15.8; 95% CI, 3.1–79; P=0.001)和男性(OR:17; 95% CI, 1.05–286; P=0.045)是发展为BrPh的危险因素。在情境模拟中,高血钾症可以通过促进静息电位升高引起的延迟和不均匀的右心室流出道激活来引起BrPh。

研究结果显示,在高血钾症患者中,Brugada 样表型与恶性心律失常和死亡呈相关性。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1842890, encodeId=3e54184289016, content=<a href='/topic/show?id=112222886b8' target=_blank style='color:#2F92EE;'>#临床特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22886, encryptionId=112222886b8, topicName=临床特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Fri Mar 15 17:38:00 CST 2019, time=2019-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081241, encodeId=33a02081241bc, content=<a href='/topic/show?id=e1ab3e481d' target=_blank style='color:#2F92EE;'>#Brugad#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3748, encryptionId=e1ab3e481d, topicName=Brugad)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Thu Dec 26 09:38:00 CST 2019, time=2019-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264680, encodeId=c71d126468050, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Sun Jan 27 01:38:00 CST 2019, time=2019-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268041, encodeId=dd1212680418b, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Jan 27 01:38:00 CST 2019, time=2019-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378587, encodeId=b05e13e8587e2, content=<a href='/topic/show?id=c142102e391f' target=_blank style='color:#2F92EE;'>#高血钾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102739, encryptionId=c142102e391f, topicName=高血钾)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64f419, createdName=qindq, createdTime=Sun Jan 27 01:38:00 CST 2019, time=2019-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535209, encodeId=03be153520961, content=<a href='/topic/show?id=099f9020145' target=_blank style='color:#2F92EE;'>#表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90201, encryptionId=099f9020145, topicName=表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6412593156, createdName=tastas, createdTime=Sun Jan 27 01:38:00 CST 2019, time=2019-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590754, encodeId=c3431590e549e, content=<a href='/topic/show?id=86e23e49d6' target=_blank style='color:#2F92EE;'>#Brugada#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3749, encryptionId=86e23e49d6, topicName=Brugada)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=939917859602, createdName=nymo, createdTime=Sun Jan 27 01:38:00 CST 2019, time=2019-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359189, encodeId=67f035918937, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d752538062, createdName=1251681am90暂无昵称, createdTime=Fri Jan 25 11:06:00 CST 2019, time=2019-01-25, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1842890, encodeId=3e54184289016, content=<a href='/topic/show?id=112222886b8' target=_blank style='color:#2F92EE;'>#临床特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22886, encryptionId=112222886b8, topicName=临床特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Fri Mar 15 17:38:00 CST 2019, time=2019-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081241, encodeId=33a02081241bc, content=<a href='/topic/show?id=e1ab3e481d' target=_blank style='color:#2F92EE;'>#Brugad#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3748, encryptionId=e1ab3e481d, topicName=Brugad)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Thu Dec 26 09:38:00 CST 2019, time=2019-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264680, encodeId=c71d126468050, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Sun Jan 27 01:38:00 CST 2019, time=2019-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268041, encodeId=dd1212680418b, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Jan 27 01:38:00 CST 2019, time=2019-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378587, encodeId=b05e13e8587e2, content=<a href='/topic/show?id=c142102e391f' target=_blank style='color:#2F92EE;'>#高血钾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102739, encryptionId=c142102e391f, topicName=高血钾)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64f419, createdName=qindq, createdTime=Sun Jan 27 01:38:00 CST 2019, time=2019-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535209, encodeId=03be153520961, content=<a href='/topic/show?id=099f9020145' target=_blank style='color:#2F92EE;'>#表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90201, encryptionId=099f9020145, topicName=表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6412593156, createdName=tastas, createdTime=Sun Jan 27 01:38:00 CST 2019, time=2019-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590754, encodeId=c3431590e549e, content=<a href='/topic/show?id=86e23e49d6' target=_blank style='color:#2F92EE;'>#Brugada#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3749, encryptionId=86e23e49d6, topicName=Brugada)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=939917859602, createdName=nymo, createdTime=Sun Jan 27 01:38:00 CST 2019, time=2019-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359189, encodeId=67f035918937, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d752538062, createdName=1251681am90暂无昵称, createdTime=Fri Jan 25 11:06:00 CST 2019, time=2019-01-25, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1842890, encodeId=3e54184289016, content=<a href='/topic/show?id=112222886b8' target=_blank style='color:#2F92EE;'>#临床特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22886, encryptionId=112222886b8, topicName=临床特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Fri Mar 15 17:38:00 CST 2019, time=2019-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081241, encodeId=33a02081241bc, content=<a href='/topic/show?id=e1ab3e481d' target=_blank style='color:#2F92EE;'>#Brugad#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3748, encryptionId=e1ab3e481d, topicName=Brugad)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Thu Dec 26 09:38:00 CST 2019, time=2019-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264680, encodeId=c71d126468050, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Sun Jan 27 01:38:00 CST 2019, time=2019-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268041, encodeId=dd1212680418b, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Jan 27 01:38:00 CST 2019, time=2019-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378587, encodeId=b05e13e8587e2, content=<a href='/topic/show?id=c142102e391f' target=_blank style='color:#2F92EE;'>#高血钾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102739, encryptionId=c142102e391f, topicName=高血钾)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64f419, createdName=qindq, createdTime=Sun Jan 27 01:38:00 CST 2019, time=2019-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535209, encodeId=03be153520961, content=<a href='/topic/show?id=099f9020145' target=_blank style='color:#2F92EE;'>#表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90201, encryptionId=099f9020145, topicName=表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6412593156, createdName=tastas, createdTime=Sun Jan 27 01:38:00 CST 2019, time=2019-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590754, encodeId=c3431590e549e, content=<a href='/topic/show?id=86e23e49d6' target=_blank style='color:#2F92EE;'>#Brugada#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3749, encryptionId=86e23e49d6, topicName=Brugada)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=939917859602, createdName=nymo, createdTime=Sun Jan 27 01:38:00 CST 2019, time=2019-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359189, encodeId=67f035918937, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d752538062, createdName=1251681am90暂无昵称, createdTime=Fri Jan 25 11:06:00 CST 2019, time=2019-01-25, status=1, ipAttribution=)]
    2019-01-27 般若傻瓜
  4. [GetPortalCommentsPageByObjectIdResponse(id=1842890, encodeId=3e54184289016, content=<a href='/topic/show?id=112222886b8' target=_blank style='color:#2F92EE;'>#临床特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22886, encryptionId=112222886b8, topicName=临床特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Fri Mar 15 17:38:00 CST 2019, time=2019-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081241, encodeId=33a02081241bc, content=<a href='/topic/show?id=e1ab3e481d' target=_blank style='color:#2F92EE;'>#Brugad#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3748, encryptionId=e1ab3e481d, topicName=Brugad)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Thu Dec 26 09:38:00 CST 2019, time=2019-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264680, encodeId=c71d126468050, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Sun Jan 27 01:38:00 CST 2019, time=2019-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268041, encodeId=dd1212680418b, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Jan 27 01:38:00 CST 2019, time=2019-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378587, encodeId=b05e13e8587e2, content=<a href='/topic/show?id=c142102e391f' target=_blank style='color:#2F92EE;'>#高血钾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102739, encryptionId=c142102e391f, topicName=高血钾)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64f419, createdName=qindq, createdTime=Sun Jan 27 01:38:00 CST 2019, time=2019-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535209, encodeId=03be153520961, content=<a href='/topic/show?id=099f9020145' target=_blank style='color:#2F92EE;'>#表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90201, encryptionId=099f9020145, topicName=表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6412593156, createdName=tastas, createdTime=Sun Jan 27 01:38:00 CST 2019, time=2019-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590754, encodeId=c3431590e549e, content=<a href='/topic/show?id=86e23e49d6' target=_blank style='color:#2F92EE;'>#Brugada#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3749, encryptionId=86e23e49d6, topicName=Brugada)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=939917859602, createdName=nymo, createdTime=Sun Jan 27 01:38:00 CST 2019, time=2019-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359189, encodeId=67f035918937, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d752538062, createdName=1251681am90暂无昵称, createdTime=Fri Jan 25 11:06:00 CST 2019, time=2019-01-25, status=1, ipAttribution=)]
    2019-01-27 heli0118
  5. [GetPortalCommentsPageByObjectIdResponse(id=1842890, encodeId=3e54184289016, content=<a href='/topic/show?id=112222886b8' target=_blank style='color:#2F92EE;'>#临床特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22886, encryptionId=112222886b8, topicName=临床特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Fri Mar 15 17:38:00 CST 2019, time=2019-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081241, encodeId=33a02081241bc, content=<a href='/topic/show?id=e1ab3e481d' target=_blank style='color:#2F92EE;'>#Brugad#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3748, encryptionId=e1ab3e481d, topicName=Brugad)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Thu Dec 26 09:38:00 CST 2019, time=2019-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264680, encodeId=c71d126468050, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Sun Jan 27 01:38:00 CST 2019, time=2019-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268041, encodeId=dd1212680418b, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Jan 27 01:38:00 CST 2019, time=2019-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378587, encodeId=b05e13e8587e2, content=<a href='/topic/show?id=c142102e391f' target=_blank style='color:#2F92EE;'>#高血钾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102739, encryptionId=c142102e391f, topicName=高血钾)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64f419, createdName=qindq, createdTime=Sun Jan 27 01:38:00 CST 2019, time=2019-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535209, encodeId=03be153520961, content=<a href='/topic/show?id=099f9020145' target=_blank style='color:#2F92EE;'>#表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90201, encryptionId=099f9020145, topicName=表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6412593156, createdName=tastas, createdTime=Sun Jan 27 01:38:00 CST 2019, time=2019-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590754, encodeId=c3431590e549e, content=<a href='/topic/show?id=86e23e49d6' target=_blank style='color:#2F92EE;'>#Brugada#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3749, encryptionId=86e23e49d6, topicName=Brugada)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=939917859602, createdName=nymo, createdTime=Sun Jan 27 01:38:00 CST 2019, time=2019-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359189, encodeId=67f035918937, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d752538062, createdName=1251681am90暂无昵称, createdTime=Fri Jan 25 11:06:00 CST 2019, time=2019-01-25, status=1, ipAttribution=)]
    2019-01-27 qindq
  6. [GetPortalCommentsPageByObjectIdResponse(id=1842890, encodeId=3e54184289016, content=<a href='/topic/show?id=112222886b8' target=_blank style='color:#2F92EE;'>#临床特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22886, encryptionId=112222886b8, topicName=临床特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Fri Mar 15 17:38:00 CST 2019, time=2019-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081241, encodeId=33a02081241bc, content=<a href='/topic/show?id=e1ab3e481d' target=_blank style='color:#2F92EE;'>#Brugad#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3748, encryptionId=e1ab3e481d, topicName=Brugad)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Thu Dec 26 09:38:00 CST 2019, time=2019-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264680, encodeId=c71d126468050, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Sun Jan 27 01:38:00 CST 2019, time=2019-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268041, encodeId=dd1212680418b, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Jan 27 01:38:00 CST 2019, time=2019-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378587, encodeId=b05e13e8587e2, content=<a href='/topic/show?id=c142102e391f' target=_blank style='color:#2F92EE;'>#高血钾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102739, encryptionId=c142102e391f, topicName=高血钾)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64f419, createdName=qindq, createdTime=Sun Jan 27 01:38:00 CST 2019, time=2019-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535209, encodeId=03be153520961, content=<a href='/topic/show?id=099f9020145' target=_blank style='color:#2F92EE;'>#表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90201, encryptionId=099f9020145, topicName=表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6412593156, createdName=tastas, createdTime=Sun Jan 27 01:38:00 CST 2019, time=2019-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590754, encodeId=c3431590e549e, content=<a href='/topic/show?id=86e23e49d6' target=_blank style='color:#2F92EE;'>#Brugada#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3749, encryptionId=86e23e49d6, topicName=Brugada)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=939917859602, createdName=nymo, createdTime=Sun Jan 27 01:38:00 CST 2019, time=2019-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359189, encodeId=67f035918937, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d752538062, createdName=1251681am90暂无昵称, createdTime=Fri Jan 25 11:06:00 CST 2019, time=2019-01-25, status=1, ipAttribution=)]
    2019-01-27 tastas
  7. [GetPortalCommentsPageByObjectIdResponse(id=1842890, encodeId=3e54184289016, content=<a href='/topic/show?id=112222886b8' target=_blank style='color:#2F92EE;'>#临床特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22886, encryptionId=112222886b8, topicName=临床特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Fri Mar 15 17:38:00 CST 2019, time=2019-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081241, encodeId=33a02081241bc, content=<a href='/topic/show?id=e1ab3e481d' target=_blank style='color:#2F92EE;'>#Brugad#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3748, encryptionId=e1ab3e481d, topicName=Brugad)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Thu Dec 26 09:38:00 CST 2019, time=2019-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264680, encodeId=c71d126468050, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Sun Jan 27 01:38:00 CST 2019, time=2019-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268041, encodeId=dd1212680418b, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Jan 27 01:38:00 CST 2019, time=2019-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378587, encodeId=b05e13e8587e2, content=<a href='/topic/show?id=c142102e391f' target=_blank style='color:#2F92EE;'>#高血钾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102739, encryptionId=c142102e391f, topicName=高血钾)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64f419, createdName=qindq, createdTime=Sun Jan 27 01:38:00 CST 2019, time=2019-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535209, encodeId=03be153520961, content=<a href='/topic/show?id=099f9020145' target=_blank style='color:#2F92EE;'>#表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90201, encryptionId=099f9020145, topicName=表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6412593156, createdName=tastas, createdTime=Sun Jan 27 01:38:00 CST 2019, time=2019-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590754, encodeId=c3431590e549e, content=<a href='/topic/show?id=86e23e49d6' target=_blank style='color:#2F92EE;'>#Brugada#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3749, encryptionId=86e23e49d6, topicName=Brugada)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=939917859602, createdName=nymo, createdTime=Sun Jan 27 01:38:00 CST 2019, time=2019-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359189, encodeId=67f035918937, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d752538062, createdName=1251681am90暂无昵称, createdTime=Fri Jan 25 11:06:00 CST 2019, time=2019-01-25, status=1, ipAttribution=)]
    2019-01-27 nymo
  8. [GetPortalCommentsPageByObjectIdResponse(id=1842890, encodeId=3e54184289016, content=<a href='/topic/show?id=112222886b8' target=_blank style='color:#2F92EE;'>#临床特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22886, encryptionId=112222886b8, topicName=临床特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Fri Mar 15 17:38:00 CST 2019, time=2019-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081241, encodeId=33a02081241bc, content=<a href='/topic/show?id=e1ab3e481d' target=_blank style='color:#2F92EE;'>#Brugad#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3748, encryptionId=e1ab3e481d, topicName=Brugad)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Thu Dec 26 09:38:00 CST 2019, time=2019-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264680, encodeId=c71d126468050, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Sun Jan 27 01:38:00 CST 2019, time=2019-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268041, encodeId=dd1212680418b, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Jan 27 01:38:00 CST 2019, time=2019-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378587, encodeId=b05e13e8587e2, content=<a href='/topic/show?id=c142102e391f' target=_blank style='color:#2F92EE;'>#高血钾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102739, encryptionId=c142102e391f, topicName=高血钾)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64f419, createdName=qindq, createdTime=Sun Jan 27 01:38:00 CST 2019, time=2019-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535209, encodeId=03be153520961, content=<a href='/topic/show?id=099f9020145' target=_blank style='color:#2F92EE;'>#表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90201, encryptionId=099f9020145, topicName=表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6412593156, createdName=tastas, createdTime=Sun Jan 27 01:38:00 CST 2019, time=2019-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590754, encodeId=c3431590e549e, content=<a href='/topic/show?id=86e23e49d6' target=_blank style='color:#2F92EE;'>#Brugada#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3749, encryptionId=86e23e49d6, topicName=Brugada)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=939917859602, createdName=nymo, createdTime=Sun Jan 27 01:38:00 CST 2019, time=2019-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359189, encodeId=67f035918937, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d752538062, createdName=1251681am90暂无昵称, createdTime=Fri Jan 25 11:06:00 CST 2019, time=2019-01-25, status=1, ipAttribution=)]
    2019-01-25 1251681am90暂无昵称

    值得学习

    0

相关资讯

JACC:隐匿性血栓患者卵圆孔封堵术后远期临床预后研究

卵圆孔(PFO)封堵术是隐匿性卒中伴PFO的标准治疗手段,然而PFO封堵术后的远期预后尚不清楚。本研究的目的旨在评估经导管PFO术后远期(10年后)的临床结局(死亡、缺血性和出血性事件)。本研究纳入了201名由于隐匿性栓塞接受经导管PFO封堵术的患者(平均年龄47±12岁,女性占51%),并对所有患者术后1个月和6个月进行了超声心动图检查,经过平均12年时间的随访,共有96%的患者完成了所有随访。

JAHA:抽烟会增加外周动脉疾病风险

与非西班牙裔的白种人相比,黑种人的外周动脉疾病(PAD)发病率要明显更高,但是抽烟在黑种人的PAD发生中的影响尚不清楚。本研究的目的旨在评估抽烟对黑种人PAD发生的影响。本研究纳入了JHS临床研究中的5306名黑种人,根据自我报告将研究对象分为现在抽烟、以前抽烟(至少400支)和从不抽烟,分析结果显示,有3579名(68%)研究对象从不抽烟,986名(19%)过去抽烟,693名(13%)现在抽烟,

JACC:正常水平内高敏肌钙蛋白越高,胸痛患者心梗风险越高

由于心血管危险因素的多样性,评估门诊胸痛的病人是否有冠心病(CAD)是一件比较困难的事情。本研究的目的旨在评估正常水平高敏肌钙蛋白(hsTnI)单分子水平上的计数对门诊胸痛患者的诊断价值。本研究纳入了PROMISE 临床研究中留有血样本的患者,并对其hsTnI水平进行了分析,主要终点事件是1年后的死亡、急性心梗或因不稳定心绞痛住院,次要终点事件是心源性死亡或急性心梗的复合事件。最终,共纳入分析了4

BMJ:油炸食物与全因、心血管及肿瘤死亡风险

研究认为,油炸食品,特别是炸鸡和炸鱼类,导致女性全因死亡及心血管死亡风险增加

盘点:JACC一月第二期研究一览

1.利伐沙班联合阿司匹林不能减少冠脉搭桥术后移植失败率DOI: 10.1016/j.jacc.2018.10.048http://www.onlinejacc.org/content/73/2?current-issue=y 接受冠脉搭桥(CABG)手术的病人早期容易发生移植失败,且会增加心梗和死亡的风险。在COMPASS 临床研究中,利伐沙班2.5mg一天两次联

JACC:房颤对退行性二尖瓣反流病人预后的影响

指南中对于房颤合并退行性二尖瓣反流(DMR)患者是否需要接受外科手术尚存在争议。本研究的目的旨在评估房颤伴DMR患者的长期预后。本研究纳入分析了MIDA 临床研究中的2425DMR名患者(年龄 67±13岁,男性占71%,无症状的占67%,射血分数为64±10%),其中1646名患者在诊断的时候为窦性心律(SR),462名患有持续性房颤。在随访期间,阵发性或持续性房颤与死亡率增高相关( p <